GSK Forms Collaboration With Oxford BioTherapeutics to Discover Antibody-Based Cancer Treatments

MT Newswires Live

12/10

GSK (GSK) has formed a strategic collaboration with Oxford BioTherapeutics to discover antibody-based cancer treatments, the UK-based oncology company said Wednesday.

The multi-year collaboration leverages GSK's drug development capabilities and Oxford's OGAP-Verify discovery platform to identify potential candidates, which will be validated through joint research, Oxford said.

The deal entitles Oxford to receive an undisclosed upfront payment, potential milestone payments and sales royalties.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2590307701"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590307701\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590307701?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 16:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590307701","market":"hk","top_or_hot":-1,"title":"GSK Forms Collaboration With Oxford BioTherapeutics to Discover Antibody-Based Cancer Treatments","media":"MT Newswires Live","content":"<html><body><p> GSK (GSK) has formed a strategic collaboration with Oxford BioTherapeutics to discover antibody-based cancer treatments, the UK-based oncology company said Wednesday.</p><p>The multi-year collaboration leverages GSK's drug development capabilities and Oxford's OGAP-Verify discovery platform to identify potential candidates, which will be validated through joint research, Oxford said.</p><p>The deal entitles Oxford to receive an undisclosed upfront payment, potential milestone payments and sales royalties.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK Forms Collaboration With Oxford BioTherapeutics to Discover Antibody-Based Cancer Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK Forms Collaboration With Oxford BioTherapeutics to Discover Antibody-Based Cancer Treatments\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-12-10 16:58</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> GSK (GSK) has formed a strategic collaboration with Oxford BioTherapeutics to discover antibody-based cancer treatments, the UK-based oncology company said Wednesday.</p><p>The multi-year collaboration leverages GSK's drug development capabilities and Oxford's OGAP-Verify discovery platform to identify potential candidates, which will be validated through joint research, Oxford said.</p><p>The deal entitles Oxford to receive an undisclosed upfront payment, potential milestone payments and sales royalties.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590307701","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590307701","pubTimestamp":1765357086,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"GSK  has formed a strategic collaboration with Oxford BioTherapeutics to discover antibody-based cancer treatments, the UK-based oncology company said Wednesday.The multi-year collaboration leverages GSK's drug development capabilities and Oxford's OGAP-Verify discovery platform to identify potential candidates, which will be validated through joint research, Oxford said.The deal entitles Oxford to receive an undisclosed upfront payment, potential milestone payments and sales royalties.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","BK4202":"服装、服饰与奢侈品","BK4532":"文艺复兴科技持仓","LU1861220207.SGD":"Blackrock FinTech A2 SGD-H","LU1829250122.USD":"高盛欧洲核心股票组合Acc","GSK.UK":"葛兰素史克","BK4007":"制药","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","LU1861217088.USD":"贝莱德金融科技A2","BK4166":"消费信贷","GSK":"葛兰素史克","DFS":"发现金融","OXM":"牛津工业","LU0106831901.USD":"贝莱德世界金融基金A2","BK4585":"ETF&股票定投概念","LU2360107671.USD":"BGF FINTECH \"A4\" (USD) INC"},"translate_title":"GSK与Oxford BioTherapeutics合作发现基于抗体的癌症治疗方法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1.5,"GSK.UK":0.6,"DFS":1.5,"OXM":1.5},"content_text":"GSK (GSK) has formed a strategic collaboration with Oxford BioTherapeutics to discover antibody-based cancer treatments, the UK-based oncology company said Wednesday.The multi-year collaboration leverages GSK's drug development capabilities and Oxford's OGAP-Verify discovery platform to identify potential candidates, which will be validated through joint research, Oxford said.The deal entitles Oxford to receive an undisclosed upfront payment, potential milestone payments and sales royalties.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}